NewsRx

Search our medical news database

3DIcon Corporation

3DIcon Files International Patent Applications for CSpaceŽ

Published in Lab Business Week, March 22nd, 2009

3DIcon Corporation (OTCBB:TDCP), a development-stage technology company, announced it has submitted patent applications for its breakthrough 3D imaging technology - CSpaceŽ - in Japan and with the European Patent Office, which covers 32 countries.

The proprietary 3D display system - CSpace - provides true, single-color, high-resolution, 360-degree, three-dimensional images without any viewing aids. It is the first proven technology of its kind that has no mechanical moving parts. 3D imaging systems developed using CSpace will have the potential to increase accuracy in real-time decision-making and can potentially expedite procedures in multiple applications. The Company...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook